Clinical trial • Phase III • Gastroenterology

Clinical trial in Cholangitis

Phase III trial for Cholangitis. 56 participants.

Overview

Trial Therapeutic Area
Gastroenterology
Trial Disease
Cholangitis
Trial Stage
Phase III

Key dates

Initial CTIS Submission Date
09-08-2024
First CTIS Authorization Date
08-09-2024

Trial design

Phase III trial across 1 site in Austria.

Target Sample Size
56
Trial Duration For Participant
601

Eligibility

Recruits 56 Vulnerable population not selected; no special consent or assent handling described..

Vulnerable Population
Vulnerable population not selected; no special consent or assent handling described.

Recruitment

Planned Sample Size
56
Recruitment Window Months
19

Geography

Total Number Of Sites
1
Total Number Of Participants
56

Austria

Earliest CTIS Part Ii Submission Date
20-08-2024
Latest Decision Or Authorization Date
08-09-2024
Processing Time Days
19
Number Of Sites
1
Number Of Participants
56

Sites

Site Name
Medical University Of Vienna
Department Name
Department of Clinical Pharmacology
Principal Investigator Name
Markus Zeitlinger
Principal Investigator Email
markus.zeitlinger@meduniwien.ac.at
Contact Person Name
Markus Zeitlinger
Number Of Participants
56

Sponsor

Primary sponsor

Full Name
Medical University Of Vienna
Organisation Type
Educational Institution
Country Of Registered Address
Austria

Related trials

Other published trials that may interest you.